What's breaking now, across thousands of outlets.
One blood marker could show if a patient has serous tubal intraepithelial carcinoma, an early sign of advanced ovarian cancer.
We haven't written up this one. Newsweek has the full story — the link below goes straight to it.
Plus, news about Vor Bio, RemeGen, Merck KGaA, Aidea, Astellas and Immuneering. BioNTech acquires PRV for $205 million: The German biotech scooped up the FDA voucher from Scholar Rock, with plans ...
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
With a standardized cell naming system and infrastructure for data collection and analysis, the basal ganglia project sets the stage for a whole-brain primate atlas.
The World Bank has urged Nigerian state governments to sustain gains recorded in child survival, malaria prevention, and immunisation under the IMPACT proj Read More…
EnGene’s latest data on its bladder cancer therapy looked better than an earlier cut in May, which had gutted the biotech’s stock after it reported underwhelming durability results.
Jaylen Watson underwent successful shoulder surgery after trying "every single possible" thing to keep playing through the injury.
